Table 2 Clinical pathological characteristic of breast cancer patients associating with CLDN6 expression

Breast cancer tissues

30

7 (23.33 %)

23 (76.67 %)

Pericarcinomatous tissues

10

10 (100 %)

0 (0 %)

P < 0.05

Age (years)

 20–40

9

2 (22.22 %)

7 (77.78 %)

 40–60

14

3 (21.43 %)

11 (78.57 %)

 60–80

7

2 (28.57 %)

5 (71.43 %)

P > 0.05

Tumor status

 T1

13

2 (15.38 %)

11 (84.62 %)

 T2

12

4 (33.33 %)

8 (66.67 %)

 T3

5

1 (20 %)

4 (80 %)

P > 0.05

Clinical stage

 Is-I

14

4 (28.57 %)

10 (71.43 %)

 II-IV

16

3 (18.75 %)

13 (81.25 %)

P > 0.05

Node status

 +

19

2 (10.53 %)

17 (89.47 %)

 –

11

5 (45.45 %)

6 (54.55 %)

P < 0.05